Strong Financial Performance
Consolidated net sales increased by 24% to $309.3 million. Adjusted EBITDA surged 64% to $18.7 million, demonstrating strong demand in the animal health business and contributions from the Zoetis MFA portfolio.
Animal Health Segment Growth
Animal health segment sales grew by 33% to $229.4 million. Legacy MFA and other product sales increased by 11%, vaccines expanded by 12%, and nutritional specialties rose by 11%.
Zoetis MFA Integration Success
Successful integration of the Zoetis medicated feed additive portfolio with two months of contributions amounting to $36.7 million in sales, driving overall MFA growth to 47%.
Updated Guidance Reflects Growth
Updated fiscal year 2025 guidance includes net sales of $1.25 billion to $1.3 billion, reflecting growth of 23% to 28%. Total adjusted EBITDA is expected to grow by 55% to 62%.
Operational Excellence and Strategic Initiatives
Phibro Forward initiative continues to drive operational excellence with focus on strategic innovation, targeted portfolio expansion, and disciplined financial management.